Keymed Biosciences Inc.
康諾亞生物醫藥科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2162)

VOLUNTARY ANNOUNCEMENT
THE LATEST RESULTS FROM A PHASE I CLINICAL STUDY OF CMG901 (AZD0901) AT THE ASCO ANNUAL MEETING 2024 BY WAY OF ORAL PRESENTATION

This announcement is made by Keymed Biosciences Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The Company is pleased to announce that the latest data from a Phase I clinical study of CMG901 (also known as AZD0901), a Claudin 18.2-targeted antibody-drug conjugate, in the treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer has been presented by way of oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. This presentation represents an update of previously presented data at November 2023 session of the ASCO Plenary Series, with a median follow-up of 10.1 months.

The KYM901 trial (NCT04805307) was designed to evaluate the safety and tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of CMG901 in patients with advanced solid tumors. As of February 24, 2024, a total of 113 patients with G/GEJ cancer received CMG901 at doses of 2.2 mg/kg, 2.6 mg/kg and 3.0 mg/kg (n=44, 50, and 19, respectively). The median lines of prior therapy of the patients was two. 74% of patients previously received anti-PD-1/PD-L1 therapy.

Among 89 evaluable patients with Claudin 18.2-high (defined as ≧2+ membrane staining intensity in ≧20% tumor cells) G/GEJ cancer in the 2.2-3.0 mg/kg cohorts, the confirmed objective response rate (ORR) and confirmed disease control rate (DCR) were 35% and 70%, respectively. A confirmed ORR of 48% was observed in the 2.2 mg/kg cohort. For all 93 patients with Claudin 18.2-high G/GEJ cancer, the median progression-free survival (mPFS) and the median overall survival (mOS) were 4.8 months and 11.8 months, respectively.

In terms of safety, among the 113 patients with G/GEJ cancer in the 2.2-3.0 mg/kg cohorts, drug-related grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 55% of patients, and drug-related serious AEs were reported in 32% of patients. 8% of patients discontinued CMG901 treatment due to drug-related AEs.

Overall, CMG901 had a manageable safety and tolerability profile, and most adverse events were well-managed through prophylactic medications or standard treatment management while continuing CMG901 treatment. CMG901 demonstrated promising efficacy in patients with advanced Claudin 18.2-high G/GEJ cancer.

ABOUT CMG901 (AZD0901)

CMG901 (AZD0901) is a potential first-in-class antibody-drug conjugate targeting Claudin 18.2 that is conjugated to monomethyl auristatin E (MMAE) through a linker, currently being evaluated by AstraZeneca in multiple clinical studies in patients with advanced solid tumors (gastric and pancreatic). Claudin 18.2 is a promising therapeutic target for advanced gastric cancer or gastroesophageal junction adenocarcinoma.

This announcement is made by the Company on a voluntary basis to provide information to the shareholders and potential investors of the Company. There is no assurance that CMG901 will ultimately be launched, developed and commercialized successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of Directors
Keymed Biosciences Inc.
Dr. Bo CHEN
Chairman

Hong Kong, June 2, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Bo CHEN, Dr. Changyu WANG and Dr. Gang XU as executive Directors; Mr. Qi CHEN, Dr. Min Chuan WANG and Mr. Yilun LIU as non-executive Directors; and Prof. Xiao-Fan WANG, Prof. Yang KE and Mr. Cheuk Kin Stephen LAW as independent non-executive Directors.